ZLAB - Zai Lab Limited

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
35.59
-0.33 (-0.92%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close35.92
Open36.15
Bid33.60 x 1000
Ask0.00 x 800
Day's Range35.49 - 36.29
52 Week Range14.29 - 36.78
Volume107,818
Avg. Volume231,912
Market Cap2.077B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Business Wire20 days ago

    Incyte and Zai Lab Announce Collaboration and License Agreement for INCMGA0012 in Greater China

    Incyte (INCY) and Zai Lab Ltd. (ZLAB) today announced that the companies have entered into a collaboration and license agreement for the development and commercialization of INCMGA0012, an investigational anti-PD-1 monoclonal antibody, in Greater China. Under the terms of the agreement, Zai Lab will pay Incyte US$17.5 million up front, and Incyte is eligible to receive up to an additional US$60 million in potential development, regulatory and commercial milestones, as well as tiered royalties from the low to mid-twenties, with Incyte responsible for all royalties and pass-through payments to its licensing partner, MacroGenics, Inc. Zai Lab will receive the rights to develop and exclusively commercialize INCMGA0012 in hematology and oncology in mainland China, Hong Kong, Macau and Taiwan.

  • GlobeNewswirelast month

    Zai Lab Announces Approval to Commercialize ZEJULA (Niraparib) in Macau for Patients with Relapsed Ovarian Cancer

    SHANGHAI, China and SAN FRANCISCO, June 12, 2019 -- Zai Lab Limited (NASDAQ: ZLAB), a Shanghai-based innovative commercial stage biopharmaceutical company, today announced its.

  • GlobeNewswirelast month

    Deciphera Pharmaceuticals, Inc. and Zai Lab Limited Announce an Exclusive License Agreement for Ripretinib in Greater China

    Deciphera Pharmaceuticals, Inc. (DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, and Zai Lab Ltd. (ZLAB), a China and U.S.-based innovative biopharmaceutical company, today announced an exclusive license agreement to advance the development and commercialization of ripretinib in Greater China (mainland China, Hong Kong, Macau and Taiwan). Discovered and developed by Deciphera, ripretinib is an investigational, oral, kinase switch control inhibitor in clinical development for the treatment of GIST and other solid tumors driven by KIT or PDGFRα.

  • GlobeNewswire2 months ago

    Zai Lab Appoints Valeria Fantin, Ph.D., as Chief Scientific Officer

    Zai Lab Limited (ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced the appointment of Valeria Fantin, Ph.D. as Chief Scientific Officer. Dr. Fantin will lead the Company’s internal drug discovery effort on a global basis and will be based in the Company’s U.S. Headquarters in San Francisco, reporting to Dr. Samantha Du.  Dr. Fantin joins Zai Lab from ORIC Pharmaceuticals, where she served as Chief Scientific Officer. “Valeria is an accomplished research leader and brings more than 20 years of oncology drug discovery expertise and research experience to Zai Lab,” said Dr. Samantha Du, Zai Lab’s Founder and Chief Executive Officer.

  • GlobeNewswire2 months ago

    Zai Lab Announces Presentations at June Conferences

    SHANGHAI, China, May 29, 2019 -- Zai Lab Limited (NASDAQ:ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that members of.

  • GlobeNewswire2 months ago

    Zai Lab Announces CTA Approval to Initiate a Phase 3 Clinical Trial of ETX2514SUL for the Treatment of Carbapenem-Resistant Acinetobacter Infections

    Zai Lab Limited (ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that the China National Medical Products Administration (NMPA) has accepted the Company’s Clinical Trial Application (CTA) to allow for the initiation of a Phase 3 clinical trial to evaluate the safety and efficacy of ETX2514SUL, a fixed-dosed combination of a broad spectrum β-lactamase inhibitor with sulbactam, for the treatment of patients with pneumonia and blood stream infections caused by carbapenem-resistant A. baumannii. “Carbapenem-resistant A. baumannii infections are a very serious public health problem in China because options to treat them are quite limited leading to a high mortality rate,” said Harald Reinhart, M.D., Chief Medical Officer of Zai Lab.

  • GlobeNewswire2 months ago

    Zai Lab Announces Participation at Upcoming May Conferences

    SHANGHAI, China, May 09, 2019 -- Zai Lab Limited (NASDAQ:ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that members of.

  • GlobeNewswire3 months ago

    Zai Lab Announces Pricing of Public Offering of American Depositary Shares

    SHANGHAI, China, May 02, 2019 -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company,.

  • GlobeNewswire3 months ago

    Zai Lab Announces Proposed Public Offering of American Depositary Shares

    SHANGHAI, China, May 01, 2019 -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ:ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today.

  • GlobeNewswire3 months ago

    Zai Lab to Host Analyst & Investor Day on April 30, 2019

    SHANGHAI, China, April 17, 2019 -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that it will.

  • GlobeNewswire4 months ago

    Zai Lab Announces Presentations at March Conferences

    SHANGHAI, China, March 12, 2019 -- Zai Lab Limited (NASDAQ:ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that members of.

  • GlobeNewswire5 months ago

    Zai Lab Announces Financial Results and Corporate Update for Full Year 2018

    -- Zai Lab to Host Conference Call and Webcast Today at 8:30 a.m. EST-- SHANGHAI, China, March 07, 2019 -- Zai Lab Limited (“Zai lab” or the Company) (NASDAQ: ZLAB), a China.

  • GlobeNewswire5 months ago

    Zai Lab to Announce Full Year 2018 Financial Results

    SHANGHAI, China, Feb. 21, 2019 -- Zai Lab Limited (NASDAQ: ZLAB), a China and US-based innovative commercial stage biopharmaceutical company, today announced that it will.

  • GlobeNewswire5 months ago

    Zai Lab to Present at the 8th Annual SVB Leerink Global Healthcare Conference

    SHANGHAI, China, Feb. 20, 2019 -- Zai Lab Limited (NASDAQ:ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that Tao Fu,.

  • GlobeNewswire6 months ago

    Zai Lab Announces the Appointment of Immuno-Oncology Pioneer, Lieping Chen, M.D., Ph.D., to its Scientific Advisory Board

    Zai Lab Limited (ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced the appointment of immuno-oncology pioneer, Lieping Chen, M.D., Ph.D., to its Scientific Advisory Board (SAB). Dr. Chen will advise the Company as it continues to advance its pre-clinical, internally-developed oncology pipeline. “It is an honor to welcome a physician-scientist of such stature to join our SAB,” said Dr. Samantha Du, Chairman and Chief Executive Officer of Zai Lab.

  • GlobeNewswire6 months ago

    Priority Review Granted to Zai Lab’s NDA Application for ZEJULA (Niraparib) in China

    Zai Lab Limited (ZLAB), a China and US-based innovative commercial stage biopharmaceutical company, today announced that the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA, formally known as CFDA) has granted priority review status to the New Drug Application (NDA) for ZEJULA (niraparib, or ZL-2306) for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal ovarian cancer who are in a complete or partial response to platinum-based chemotherapy. Zai Lab in-licensed rights to ZEJULA from Tesaro for China, Hong Kong and Macau as an important, new treatment option for more than 50,000 Chinese patients who suffer from ovarian cancer every year.

  • GlobeNewswire6 months ago

    Zai Lab Completes Enrollment of China Pivotal Trial of Niraparib as Second-Line Maintenance Therapy for Ovarian Cancer in China

    “Completion of patient enrollment of this pivotal trial is an important milestone for Zai as it further demonstrates our clinical development capabilities and commitment to our clinical investigators and ovarian patients in China,” said Dr. Samantha Du, Founder and Chief Executive Officer of Zai Lab. The Phase 3 trial is evaluating niraparib as a second-line maintenance therapy in patients with recurrent platinum-sensitive ovarian cancer. Recurrent ovarian cancer patients who have responded to a platinum-containing regimen were enrolled in the study and randomized 2:1 to receive either niraparib or placebo once daily.

  • GlobeNewswire7 months ago

    Zai Lab Announces Launch of Optune® in Hong Kong for Patients with Glioblastoma Multiforme

    Zai Lab (ZLAB) today announced the launch of Optune® (Tumor Treating Fields or TTFields) in Hong Kong for the treatment of glioblastoma multiforme (GBM) with the treatment of its first patient. Hong Kong is the fourth market after the United States, Europe and Japan to have access to this important new medical technology.

  • GlobeNewswire7 months ago

    Zai Lab to Present at the 37th Annual J.P. Morgan Healthcare Conference

    SHANGHAI, China, Dec. 19, 2018 -- Zai Lab Limited (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced that Dr. Samantha Du, Founder and Chief.

  • GlobeNewswire7 months ago

    Zai Lab Announces Acceptance of NDA Submission of ZEJULA (Niraparib) in Mainland China by the NMPA

    Zai Lab Limited (ZLAB), a Shanghai-based innovative commercial stage biopharmaceutical company, today announced that the China National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for ZEJULA (niraparib, or ZL-2306) as a Category 1 drug for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal ovarian cancer who are in a complete or partial response to platinum-based chemotherapy. “The NMPA’s acceptance of our NDA submission for ZEJULA represents a major milestone for Zai Lab as this is our first ever NDA submission in Mainland China,” said Dr. Samantha Du, Founder and Chief Executive Officer of Zai Lab.

  • GlobeNewswire8 months ago

    MacroGenics and Zai Lab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Margetuximab, MGD013 and TRIDENT™ Molecule in Greater China

    Margetuximab, an immune-optimized anti-HER2 monoclonal antibody currently being evaluated in Phase 3 metastatic breast cancer with anticipated topline results in the first quarter of 2019. Zai Lab obtains regional development and commercialization rights for these programs in mainland China, Hong Kong, Macau and Taiwan.

  • GlobeNewswire8 months ago

    Zai Lab and Novocure Awarded Deal of the Year

    Zai Lab Limited (ZLAB), a Shanghai-based innovative biopharmaceutical company, and Novocure Limited (NVCR) today announced that they have received the Deal of the Year Award at the 9th Annual BayHelix Awards Lunch Banquet held during the annual BioCentury-BayHelix China Healthcare Summit in Shanghai, China. The annual award recognizes a groundbreaking collaboration, technology transfer, licensing, capital raising, M&A or joint venture that involves a Chinese company in the healthcare sector. In September of this year, Zai Lab and Novocure announced a strategic collaboration and an exclusive license agreement in the field of oncology by which Zai lab would develop and launch Novocure’s Tumor Treating Fields (TTFields) technology, under the brand name Optune®, in Greater China and to collaborate with Novocure in the global development of the product.  TTFields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to die.

  • GlobeNewswire8 months ago

    Zai Lab Limited Announces Presentations at November Conferences

    SHANGHAI, China, Nov. 07, 2018 -- Zai Lab Limited (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced that members of the senior management.